Asset Details
Do you wish to reserve the book?
Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
Do you wish to request the book?
Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
2019
Overview
Background
Parkinson’s disease (PD) and drug-induced parkinsonism (DIP) are the major diseases of parkinsonism. To better understand parkinsonism, we aimed to assess the prevalence and incidence of PD and DIP in Korea from 2012 to 2015.
Methods
We used the Health Insurance Review and Assessment Service database, which covers the entire population in Korea. We used claims during 2011–2015 to assess epidemiology of PD and DIP during 2012–2015. Retrospective cross-sectional study design was employed to assess prevalence, whereas retrospective cohort study design was used to determine incidence. Patients with at least one claim with ICD-10 G20 and who received antiparkinsonian drugs for at least 60 days were classified as having PD. We excluded patients with antiparkinsonian drugs that can be used for indications other than PD. Patients with at least one claim with ICD-10 G211 or G251 during the prescription period of drugs that are frequently related with DIP were classified as having DIP. Incident cases had a disease-free period of 1 year before diagnosis. To evaluate the significance of changes in the prevalence or incidence over time, Poisson regression was used to determine
p
for trend.
Results
The prevalence of PD increased from 156.9 per 100,000 persons in 2012 to 181.3 per 100,000 persons in 2015 (
p
for trend< 0.0001). The incidence of PD decreased steadily from 35.4 per 100,000 person-years in 2012 to 33.3 per 100,000 person-years in 2015 (
p
for trend< 0.0001). The prevalence of DIP increased from 7.3 per 100,000 persons in 2012 to 15.4 per 100,000 persons in 2015 (
p
for trend< 0.0001) and the incidence of DIP increased from 7.1 per 100,000 person-years in 2012 to 13.9 per 100,000 person-years in 2015 (
p
for trend< 0.0001).
Conclusions
Our study suggests that the incidence of PD has gradually decreased whereas, the incidence of DIP increased from 2012 to 2015. Further studies are warranted to examine possible causes of increased DIP incidence in order to develop management strategy for parkinsonism.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Chronic Disease epidemiology
/ Drugs
/ Female
/ Health
/ Humans
/ Male
/ Medicine
/ Parkinson Disease - diagnosis
/ Parkinson Disease - epidemiology
/ Parkinson Disease, Secondary - diagnosis
/ Parkinson Disease, Secondary - epidemiology
/ Republic of Korea - epidemiology
/ Strategic planning (Business)
/ Vaccine
